|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 213/75 | |
| A61K 31/44 | |||
| A61P 7/02 |
| (11) | Patento numeris | 2611779 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11757467.3 |
| Europos patento paraiškos padavimo data | 2011-08-31 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-07-10 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-08-10 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/050057 |
| Data | 2011-08-31 |
| (87) | Numeris | WO 2012/031017 |
| Data | 2012-03-08 |
| (30) | Numeris | Data | Šalis |
| 201161454396 P | 2011-03-18 | US | |
| 379339 P | 2010-09-01 | US |
| (72) |
CAPODANNO, Vincent, R., US
CORCORAN, Liam, IE
McNEVIN, Michael, US
ARROYO, Itzia Zoraida, US
WENSLOW, Robert, M., US
BALL, Richard, G., US
MARGELEFSKY, Eric, L., US
MAHER, Timothy, K., US
PANDEY, Anjali, US
|
| (73) |
Portola Pharmaceuticals, Inc.,
270 East Grand Avenue Suite 22, South San Francisco, California 94080,
US
|
| (54) | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR |
| CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR |